Honasa buys 58% of Fluence Pharma at ₹135 cr EV, enters ₹16,000-cr nutraceuticals via Honasa Health
Mamaearth parent Honasa Consumer is acquiring a 58% stake in nutraceuticals firm Fluence Pharma at a ₹135 crore enterprise value, with the remaining 42% to be picked up over 5-7 years. The deal launches a new subsidiary, Honasa Health, marking the BPC major's formal entry into India's ₹16,000-crore nutraceuticals category.
Honasa Consumer (Mamaearth parent) is acquiring 58% of nutraceuticals firm Fluence Pharma at ₹135 crore EV, with the remaining 42% over 5-7 years. It marks Honasa's entry into India's ₹16,000-crore nutraceuticals category via new subsidiary Honasa Health.
Why this matters
Honasa is extending its Mamaearth-led BPC playbook into nutraceuticals via a phased 58% buyout of Fluence Pharma, mirroring its strategy of category expansion through subsidiary brands like Honasa Health.
Retail-company activity steady with 3,586 signals tracked over the last 90 days.